enoxacin‘s R&D Progress
Enoxacin is a small molecule drug that falls under the therapeutic area of infectious diseases. It is primarily used to treat bacterial infections. The drug targets three key components in bacteria, namely bacterial DNA gyrase, bacterial Top II, and bacterial top IV. By targeting these components, enoxacin aims to inhibit bacterial growth and replication.
Enoxacin was first approved in the United States in December 1991, making it an established drug in the market. It is important to note that enoxacin is classified as an orphan drug, which means it is intended to treat rare diseases or conditions that affect a small number of patients. This classification may indicate that enoxacin is used to treat specific types of bacterial infections that are not commonly encountered.
The drug was developed by Sanofi, a well-known pharmaceutical organization. Sanofi is the originator organization of enoxacin, suggesting that they were responsible for its initial discovery and development. Enoxacin has reached the highest phase of development which is approved globally.
Enoxacin’s primary mode of action is to target bacterial DNA gyrase, bacterial Top II, and bacterial top IV. These components play crucial roles in bacterial replication and growth, making them attractive targets for drug intervention. By inhibiting these components, enoxacin disrupts the bacterial life cycle and prevents further infection.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for enoxacin: Bacterial DNA gyrase + Bacterial Top Il + Bacterial top IV
Bacterial DNA gyrase inhibitors, bacterial Top II inhibitors, and bacterial Top IV inhibitors are all types of drugs that target specific enzymes involved in bacterial DNA replication and cell division.
From a biomedical perspective, DNA gyrase is an essential enzyme in bacteria that helps in the supercoiling and unwinding of DNA during replication. Inhibitors of bacterial DNA gyrase, such as fluoroquinolones, work by binding to the enzyme and preventing it from carrying out its normal function. This leads to the inhibition of DNA replication and ultimately bacterial cell death.
Similarly, bacterial Topoisomerase II (Top II) and Topoisomerase IV (Top IV) are enzymes involved in the management of DNA supercoiling and separation of DNA strands during replication. Inhibitors of bacterial Top II and Top IV also interfere with the normal functioning of these enzymes, leading to DNA damage and bacterial cell death.
These classes of drugs are specifically designed to target bacterial enzymes, as they have unique structural and functional characteristics that differentiate them from their human counterparts. By selectively inhibiting these bacterial enzymes, these drugs can effectively treat bacterial infections while minimizing harm to human cells.
It is important to note that these drugs specifically target bacterial enzymes and are not effective against viruses or other types of pathogens. Additionally, the use of these drugs should be carefully monitored to prevent the development of antibiotic resistance in bacteria.
Drug Target R&D Trends for enoxacin
Bacterial DNA gyrase, bacterial topoisomerase II, and bacterial topoisomerase IV are enzymes that play crucial roles in the replication and maintenance of bacterial DNA. DNA gyrase is responsible for introducing negative supercoils into the DNA molecule, aiding in DNA replication and transcription. Bacterial topoisomerase II and topoisomerase IV are involved in the regulation of DNA topology, ensuring proper DNA segregation during cell division. These enzymes are specific to bacteria and are essential for their survival and growth. Inhibiting these enzymes with antibiotics can disrupt bacterial DNA replication and ultimately lead to bacterial cell death, making them important targets for pharmaceutical interventions.
According to Patsnap Synapse, as of 7 Sep 2023, there are a total of 1 Bacterial DNA gyrase + Bacterial Top II + Bacterial top IV drugs worldwide, from 2 organizations, covering 1 indications, and conducting 8 clinical trials.
The analysis of the current competitive landscape and future development of the target Bacterial DNA gyrase + Bacterial Top II + Bacterial top IV reveals the following key findings:
– Grand Pharmaceutical Group Limited and Sanofi are the companies growing under this target, with Grand Pharmaceutical Group Limited reaching the approved stage and Sanofi being in the inactive stage.Drugs under this target have been approved for the indication of Bacterial Infections, indicating their efficacy in treating such infections.Small molecule drugs are progressing most rapidly under this target, suggesting a focus on this drug type in research and development efforts. China and the United States are the countries/locations with the highest phase under this target, with China showing significant progress in drug development.
These findings suggest that there is active research and development in the pharmaceutical industry for drugs targeting Bacterial DNA gyrase + Bacterial Top II + Bacterial top IV. The approved drugs and the focus on small-molecule drugs indicate potential opportunities for innovation and competition in this area.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In summary, enoxacin is a small molecule drug developed by Sanofi for the treatment of bacterial infections. It targets bacterial DNA gyrase, bacterial Top II, and bacterial top IV, which are essential for bacterial replication. Enoxacin, classified as an orphan drug, has been approved in the US and China since December 1991, making it an established market drug.